Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Magnetic imaging agent
Patent
1994-03-18
1995-07-25
Hollinden, Gary E.
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Magnetic imaging agent
546183, 436173, 514299, 424 93, A61B 5055, C07D22102
Patent
active
054359910
DESCRIPTION:
BRIEF SUMMARY
The application is a 371 of PCT/EP92/01793 filed Aug. 6, 1992.
The present invention relates to the use of persistent free radicals, in particular persistent free radicals having a carbon-based .pi.-bonded electronic system available for delocalization of the unpaired electrons (hereinafter "persistent .pi.-system radicals"), as image enhancing agents in magnetic resonance imaging (MRI) as well as to contrast media containing such radicals and to the use of such radicals and their non-radical precursors in the manufacture of MRI contrast media.
MRI is a diagnostic technique that has become particularly attractive to physicians as it is non-invasive and does not involve exposing the patient under study to potentially harmful radiation, such as for example the X-radiation of conventional radiography.
This technique, however suffers from several serious drawbacks, including in particular the expense of manufacture and operation of the MRI apparatus, the relatively long scanning time require to produce an image of acceptable spatial resolution, and the problem of achieving contrast in the magnetic resonance (MR) images between tissue types having the same or closely similar imaging parameters, for example in order to cause a tissue abnormality to show up clearly in the images.
The expense of manufacture and operation of an MRI apparatus is closely associated with the strength of the magnetic field that the primary magnet in the apparatus is required to generate in order to produce images of acceptable spatial resolution in an acceptable time.
MR images are generated by manipulation of the MR signals detected from the example, for example a human or animal body, placed in a magnetic field and exposed to pulses of radiation of a frequency (typically radiofrequency (RF)) selected to excite MR transitions in selected non-zero spin nuclei (the "imaging nuclei", which are generally water protons in body fluids) in the sample.
The amplitude of the induced MR signals is dependent upon various factors such as the strength of the magnetic field experienced by the sample, the temperature of the sample, the density of the imaging nuclei within the sample, the isotopic nature and chemical environment of the imaging nuclei and the local inhomogeneities in magnetic field experienced by the imaging nuclei.
Thus many techniques have been proposed for enhancing MR image quality, for example by increasing MR signal amplitude or by increasing the difference in MR signal amplitude between different tissue types.
The imaging parameters (nuclear density, T.sub.1 and T.sub.2) for tissues of interest may be altered and many proposals have been made for doing this by the administration of magnetically responsive materials into patients under study (see for example EP-A-71564 (Schering), EP-A-133674 (Schering) and WO-A-85/04330 (Jacobsen)). Where such materials, generally referred to as MRI contrast agents, are paramagnetic they produce significant reduction in the T.sub.1 of the water protons in the body zones into which they are administered or at which they congregate, and where the materials are ferromagnetic or superparamagnetic (for example as suggested by Jacobsen) they produce a significant reduction in the T.sub.2 of the water protons. In either case the result is enhanced (positive or negative) contrast in the MR images of such zones.
The contrast enhancement achievable by such agents in conventional MRI is relatively limited and it is generally not such as to allow a reduction in the image acquisition period or in the field strength of the primary magnet.
Utilisation of the spin transition coupling phenomenon known as dynamic nuclear polarisation or as the Overhauser effect to amplify the population difference between the ground and excited spin states of the imaging nuclei by the excitation of a coupled ESR transition in a paramagnetic species present in the sample being imaged has been described by Hafslund Nycomed Innovation AB in WO-A-88/10419.
This new technique for generating a MR image of the sample, which is hereinaft
REFERENCES:
patent: 4499095 (1985-02-01), Rosseels et al.
patent: 4882327 (1989-11-01), King
patent: 4957925 (1990-09-01), Gubin et al.
patent: 4985063 (1991-01-01), Fischer et al.
patent: 5028614 (1991-07-01), Liu et al.
patent: 5066807 (1991-11-01), Anzeveno et al.
patent: 5223510 (1993-06-01), Gubin et al.
Grucker; Magnetic Resonance In Medicine, vol. 14, 1990; pp. 140-147.
Nagamura et al.; Chemical Abstracts, vol. 96, No. 10, Abstract No. 70290a, 1981.
Fessenden et al.; Chemical Abstracts, vol. 94, No. 22, Abstract No. 183019w, 1981.
Clough et al.; Chemical Abstracts, vol. 83, No. 10, Abstract No. 88194p, 1975.
Wadsworth et al.; J. Org. Chem., vol. 51, No. 24, 1986; pp. 4639-4644.
Mueller-Warmuth et al.; Chemical Abstracts, vol. 74, No. 8, Abstract No. 35176s, 1970.
Kalyanaraman et al.; The Journal Of Biological Chemistry, vol. 264, No. 19, Jul. 5, 1989; pp. 11014-11019.
Lurie et al., Journal of Magnetic Resonance, 76, 366-370 (1988).
Andersson Sven
Golman Klaes
Rise Frode
Wikstrom Hakan
Wistrand Lars-Goran
Hollinden Gary E.
Nycomed Innovation AB
LandOfFree
Use of persistent heterocyclic free-radicals in magnetic resonan does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of persistent heterocyclic free-radicals in magnetic resonan, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of persistent heterocyclic free-radicals in magnetic resonan will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-738126